Dosage Protocols Since BPC-157 is not FDA-approved for human use, there are no officially established dosing guidelines
useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established

Genistein protects epilepsy-induced brain injury through regulating the JAK2/STAT3 and Keap1/Nrf2 signaling pathways in the developing rats
et al (2015) Oncol Lett.
and TB-500: The Recovery Peptide Behind the Wolverine Stack
Thats part of the problem, says Henry Ellis, a sports medicine surgeon and researcher at the University of Texas, Southwestern, in Dallas, Texas, who has written about BPC-157 for the American Orthopedic Society for Sports Medicine (AOSSM)